NYKODE THERAPEUTICS

Insiders Nykode Therapeutics

Equities

VACC

NO0010714785

Market Closed - Oslo Bors Other stock markets 08:34:14 13/05/2024 pm IST			5-day change	1st Jan Change
14.05 ^NOK	+0.07%		+0.50%	-34.35%

19/04	Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	MT
19/04	Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nykode Therapeutics AS Announces Management Changes	11/23/11	CI
Nykode Therapeutics : Nomination Committee Proposal	20/23/20	PU
Nykode Therapeutics Names CureVac Exec As New Chief Development Officer	13/22/13	MT
Nykode Therapeutics AS Appoints Klaus Edvardsen as Chief Development Officer, Effective from July 1, 2022	13/22/13	CI
Nykode Therapeutics AS Appoints Elaine Sullivan and Anne Whitaker to the Board of Directors	12/22/12	CI
Nykode Therapeutics Names New Chair	15/21/15	MT
Vaccibody to Change Name to Nykode Therapeutics	23/21/23	MT
Vaccibody AS has Changed its Name to Nykode Therapeutics	23/21/23	CI
Vaccibody AS Announces Management Appointments, Effective June 1, 2021	12/21/12	CI
Vaccibody AS Appoints Dr. Volck as New Member of the Board	05/21/05	CI
Vaccibody AS Appoints Harald Gurvin as New Chief Financial Officer, Effective May 3, 2021	28/21/28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW